Department of General, Visceral, and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.
National Cancer Center, University of Heidelberg, Heidelberg, Germany.
Lancet Oncol. 2013 Oct;14(11):e476-e485. doi: 10.1016/S1470-2045(13)70172-4.
Surgery is the only potential hope of cure for patients with pancreatic cancer. Advantageous tumour characteristics and complete tumour resection are the factors most relevant for a positive prognosis, so detection of premalignant or early invasive lesions, combined with safe and oncologically adequate surgery, is an important goal. The experience and volume of both the individual surgeon and hospital are of paramount importance to achieve low morbidity and adequate management of complications. Most pancreatic cancers are locally advanced or metastatic when diagnosed and need multimodal therapy. With increasing evidence on surgical and perioperative aspects of pancreatic cancer therapy, short-term and long-term outcomes of resectable and borderline resectable pancreatic cancer are improving.
手术是治疗胰腺癌患者的唯一潜在希望。有利的肿瘤特征和完全肿瘤切除是与良好预后最相关的因素,因此,检测癌前或早期浸润性病变,并结合安全和肿瘤学上适当的手术,是一个重要目标。个人外科医生和医院的经验和手术量对于实现低发病率和适当处理并发症至关重要。大多数胰腺癌在诊断时已处于局部晚期或转移,需要多模式治疗。随着对胰腺癌治疗的手术和围手术期方面的证据不断增加,可切除和边缘可切除的胰腺癌的短期和长期结果正在改善。